Weight Loss Vault
Sema/Tirz Tablet
Two incretin therapies, one tablet.
A combination oral tablet pairing semaglutide and tirzepatide for patients who need broader incretin coverage under close provider supervision.
- Prescribed only after evaluation
- Start low, adjust slowly
- Protein intake and resistance training protect lean mass
Prescription only. A licensed provider determines whether Sema/Tirz Tablet is appropriate for you.
How it's taken
Daily oral combination tablet
Oversight
Licensed provider, ongoing follow-up
Delivery
Discreet shipping to your door
How it works
The science, in plain language.
Combining a GLP-1 agonist with a dual GIP/GLP-1 agonist targets appetite, satiety, and glucose handling through multiple pathways at once. Dosing is conservative and provider-directed.
Benefits
What you can expect.
- Multi-pathway appetite control
- Single daily tablet instead of two protocols
- Useful when progress stalls on one agent
- Close provider monitoring throughout
Questions
Good to know.
Why combine them?
Some patients respond better to broader incretin coverage. Your provider decides whether a combination is appropriate for you.
Is monitoring different?
Yes — combination therapy is followed more closely, with regular check-ins on tolerance and progress.
Safety
Important information.
Combination incretin therapy increases the chance of nausea, reflux, and appetite suppression. It requires provider oversight and is not appropriate for everyone.
This page is for general education and is not medical advice. Your treatment plan is determined by a licensed healthcare provider after evaluation.
Also in this vault
